Xcout Intel
Endogena Therapeutics Inc.
Endogena Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Zürich, Switzerland, that discovers and develops first-in-class endogenous regenerative medicines to repair tissues.
Subscribe to see Endogena Therapeutics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Endogena Therapeutics Inc. at a glance
Endogena Therapeutics Inc. is a biotechnology company headquartered in Switzerland. It has raised at least $37M across the 2 funding rounds on record. Its most recent funding round, Series A-1, raised $29M in November 2021. Xcout tracks 10 named people at Endogena Therapeutics Inc., including Etienne Binant (Interim CEO).
Endogena Therapeutics Inc. leadership
- Etienne BinantInterim CEO
- Susanne RaabChief Development Officer
- Mike TanjiChairman
- Gisbert SchneiderCo-Founder / ETH Zürich
- Matthias StegerFounder
- Michelle WidmannHead of Clinical Operations US
4 more named people on record for Endogena Therapeutics Inc., with roles, board committees and tenure — see the full roster →
Endogena Therapeutics Inc. funding rounds
At least $37M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A-1 | $29M | 3 named | |
| SEC Form D filing | $8M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Endogena Therapeutics Inc. competitors
A few of Endogena Therapeutics Inc.'s closest competitors — see the full list of competitors and alternatives →
Ultimate Medicine AG is a Swiss preclinical biotechnology company headquartered in Zürich, focused on maximizing the healthspan of patients with Alzheimer's disease and other dementias by targeting novel toxic metabolites.
Aspect Biosystems develops bioengineered cellular medicines and implantable tissue therapeutics using a proprietary bioprinting platform that integrates AI, computational design, and advanced biomaterials. The company serves the biotechnology and pharmaceutical industries by creating treatments to replace, repair, or supplement biological functions for metabolic and endocrine diseases.
GlycoEra AG is a biotechnology company focused on advancing glycan-mediated therapy through game-changing protein engineering. Headquartered in Wädenswil, Switzerland, the company also maintains an office in Newton, Massachusetts.
Cyclana Bio is a biotechnology company headquartered in Cambridge, United Kingdom, pioneering tissue-level approaches to advance drug discovery and uncover mechanisms in women's health.
Envisagenics, Inc. is an active biotechnology research company co-founded by Dr. Maria Luisa Pineda. Headquartered in New York City, the company applies advanced computational platforms and data analytics to discover novel therapeutics and targets for complex diseases.
Engitix is a biotechnology company that utilizes a proprietary platform based on human Extracellular Matrix (ECM) scaffolds to model and study disease biology. The company develops discovery-stage therapeutics targeting fibrosis, inflammation, and solid tumors, and forms partnerships with pharmaceutical and biotech organizations.
Get Endogena Therapeutics Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Endogena Therapeutics Inc. in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access